Tekla Capital Management’s Kyntra Bio KYNB Stock Holding History

Tekla Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,771	Closed	-$7.21M	–	207
2020 Q4	$7.21M	Hold	7,771	–	–	0.25%	98
2020 Q3	$7.99M	Hold	7,771	–	–	0.3%	78
2020 Q2	$7.87M	Hold	7,771	–	–	0.3%	69
2020 Q1	$6.75M	Hold	7,771	–	–	0.31%	65
2019 Q4	$8.33M	Sell	7,771 -1,555	-17%	-$1.59M	0.32%	75
2019 Q3	$8.62M	Sell	9,326 -447	-5%	-$491K	0.38%	58
2019 Q2	$11M	Buy	9,773 +2,743	+39%	+$3M	0.45%	54
2019 Q1	$9.55M	Sell	7,030 -1,481	-17%	-$2.01M	0.39%	54
2018 Q4	$9.85M	Buy	8,511 +1,383	+19%	+$1.55M	0.42%	46
2018 Q3	$10.8M	Hold	7,128	–	–	0.39%	61
2018 Q2	$11.2M	Buy	7,128 +2,956	+71%	+$3.85M	0.42%	55
2018 Q1	$4.82M	Buy	+4,172	New	+$5.49M	0.19%	91

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tekla Capital Management's KYNB Position: Q1 2021 in Review

Tekla Capital Management sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 7,771 shares — an estimated $7.21M sold.

Tekla Capital Management first reported a position in KYNB in Q1 2018 and held it in 12 quarters. The position peaked at $11.2M in Q2 2018. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

Tekla Capital Management reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 7,771 Kyntra Bio shares in Q1 2021, an estimated $7.21M.
Tekla Capital Management first reported a position in Kyntra Bio in Q1 2018 and held it in 12 quarters.
Tekla Capital Management's Kyntra Bio position peaked at $11.2M in Q2 2018.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.